Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Lewy body dementia.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Dementia with Lewy bodies (DLB) is perhaps the second most common cause of degenerative dementia after Alzheimer's disease. This book, which represents the first authoritative statement about DLB, arises from a workshop held in Newcastle, England, in October 1995, which brought together leading investigators with clinical and research experience of this condition. It includes review articles, case studies and recent research findings from the main centres studying DLB. Covering the classification, cognitive manifestations, clinical diagnosis, epidemiology, genetics, neuropathology, neurochemistry and treatment of DLB, this is a landmark publication in clinical neuroscience. It presents new operational criteria for research on DLB, and will interest all concerned with the problem of dementia in the elderly.

Lewy body dementia --- Lewy, Friederich Heinrich,

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Lewy body dementia --- Genetic aspects --- Parkinson's disease --- Genetic aspects

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The focus on dopamine-sensitive motor symptoms, in association with the improvement of motor complications in the heterogeneous disease entity Parkinson's disease, has led to a certain standstill in research. This Special Issue provides new concepts and new ideas on the pathogenesis, genetics, and clinical maintenance of Parkinson's disease and related disorders. Not only new experimental findings, but also clinical outcomes, case series, and research on alternative, non-pharmacological therapies are included. The objective is to bridge the currently increasing gap between experimental and clinical research on Parkinson's disease and related disorders.

microRNAs --- disease-modifying effects --- SH-SY5Y --- inpatient treatment --- sphingolipids --- neurodegeneration --- magnetic resonance spectroscopy --- MO3.13 --- schizophrenia --- epigenetics --- long-chain acylcarnitine --- molecular mimicry --- curli --- multimodal complex treatment --- chlorogenic acid --- glycerophospholipids --- caffeic acid --- lipoproteins --- myenteric plexus --- neurometabolites --- HOG --- immature oligodendrocyte --- autophagy --- oligodendrocyte --- hypochlorite --- alpha-synuclein --- microbiome --- glucocerebrosidase --- Lewy Body Dementia --- brain iron --- mesenchymal stem cells --- fatty acid ?-oxidation --- GABA --- enteric glial cell --- gut-brain axis --- microbiota --- REM sleep behavior disorders --- redox cycling --- magnetic resonance imaging --- differentiation --- ?-synuclein-mediated pathology --- Parkinson disease --- Gaucher’s disease --- metallothionein --- [123I]FP-CIT-SPECT --- dopaminergic neuron --- mature oligodendrocyte --- glycerolipids --- spectroscopy --- neuroinflammation --- exosomes --- immunotherapy --- DNA methylation --- sterol lipids --- nigral cells --- cell line --- cysteinyl-dopamine --- myelin --- parkinsonisms --- multiple sclerosis --- rotenone --- brain --- fatty acyls --- Krabbe’s disease --- neuroprotection --- DAT --- motor dysfunction --- secretome --- multiprofessional therapy --- Parkinson’s disease --- oxidative stress --- alpha-Synuclein